Combining lurbinectedin with immunotherapy may have potential side effects that should be carefully considered. Lurbinectedin, a chemotherapy drug, may interact with immunotherapy agents leading to adverse effects. Clinical trials, such as NCI-2022-00578, are investigating the safety and efficacy of combining lurbinectedin with immunotherapy in cancer treatment. The study aims to determine the side effects and benefits of this combination therapy. According to a study published in the National Center for Biotechnology Information, combining lurbinectedin with immunotherapy can enhance the immune response against cancer cells. However, this combination may also lead to increased toxicity and side effects, which should be monitored closely during treatment [3]. It is crucial for healthcare providers to carefully assess the risks and benefits of combining these treatments based on individual patient factors to optimize outcomes.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-00578
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469650/